EM-transcriptomic signature predicts drug response in advanced stages of high-grade serous ovarian carcinoma based on ascites-derived primary cultures
Article in Frontiers in Pharmacology (March 2024)
The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.
Exogenous PRAS40 reduces KLF4 expression and alleviates hypertrophic scar fibrosis and collagen deposition through inhibiting mTORC1
Article in Burns (February 2024)
A transcriptomic pan-cancer signature for potential implications in prognosis and treatment based on disulfidptosis-related gene
Preprint in Research Square (December 2023)